Rezdiffra

Rezdiffra is a prescription medication indicated for the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH) in individuals with mild to severe hepatic fibrosis. It is used to promote improved liver health in conjunction with a balanced diet and consistent exercise.

Molecule Details :

  • Molecule Name :

    Resmetirom
  • Innovator :

    MADRIGAL PHARMACEUTICALS INC
  • Approval Date :

    14-Mar-24
  • NCE-1 Date :

    14-Mar-28
  • Dosage Form :

    Tablet
  • Strength :

    60mg, 80mg, 100mg
  • Therapeutic Category :

    Antimetabolic Disorder
  • Revenue ($M) :

    180

Year-wise Projected Sales ($M) :

  • 2025 :

    607
  • 2026 :

    1,067
  • 2027 :

    1,750
  • 2028 :

    2,533
  • 2029 :

    3,482
  • 2030 :

    4,265
  • 2031 :

    4,974
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Login NCE Grid

Register NCE Grid

Are you sure want to logout from NCE Grid?